The China Drug Administration Proposes a Working Procedure for Pharmaceutical Study Data Protection

by Ropes & Gray LLP
Contact

Ropes & Gray LLP

In response to the central government’s calling for a data protection mechanism,1 the China Drug Administration (the “CDA”) published a draft on Implementing Measures for Pharmaceutical Study Data Protection (the “Draft”) on April 25, 2018 for public comments. This Draft specifies data protection scope, extends the data protection period, and, for the first time, proposes a working procedure for applying for and granting a data protection right.

To Redefine Protection Scope

Since China’s entry to the WTO in 2002, drugs containing innovative chemical entities have been entitled to six years of data exclusivity protection.2 The Draft expands the protection scope to cover both innovative drugs and generic drugs. Specifically, eligible drugs include (i) innovative drugs, (ii) innovative therapeutic biologics, (iii) orphan drugs, (iv) pediatric drugs, and (v) generic drugs to which pertinent patents have been invalidated.

The current data protection mechanism protects independently generated and undisclosed study data and other data. The Draft narrows the scope of protected data to those independently generated and undisclosed non-clinical and clinical study data that is submitted for marketing authorization purposes only if they are related to product efficacy. Product safety data in the regulatory submissions is excluded from protection.

To Extend Protection Period

The Draft offers a variety of protection periods up to 12 years (for details, please see the table below). The level of protection is on par with what the USFDA offers3 and surpasses what the EMEA provides.4

Drugs

Protection Period

Innovative drugs

6 years from the date of marketing authorization in China

Innovative therapeutic biologics

12 years from the date of marketing authorization in China

Orphan drugs

6 years from the date of the first approval of the relevant indication in China

Pediatric drugs

6 years from the date of the first approval of the relevant indication in China

Generic drugs to which pertinent patents have been invalidated (i.e., first-to-market generics)

Unclear

 
To incentivize early launches of new drugs in China, the protection period for an innovative drug will be reduced by one to five years if the New Drug Approval (NDA) application is first filed outside China in reliance of data from multi-regional clinical studies on Chinese patients. No protection will be granted if such NDA application is filed six years later than the first foreign filing. Further, a protection period will be reduced (i) by 75% if a NDA application is solely based on overseas clinical data or (ii) by 50% if such NDA application is based on supplemental studies on Chinese subjects.

To Provide an Implementing Mechanism

The Draft introduces a working procedure for pharmaceutical companies to apply for and exercise its data protection right. An NDA applicant can apply for a study data protection right in the NDA application with the CDA. The CDA may grant a data protection right together with the relevant NDA. Information about the rationale for data protection and its exclusivity term will be publically available in China’s Orange Book.

If any subsequent application concerns a drug having the same active ingredient and indication as that of a protected drug during the exclusivity term, the CDA will notify the relevant data protection right owner within 30 days after its receipt of the application. The right owner can oppose this application within 30 days after receiving the notification. If the right owner opposes, the CDA will verify and decide on the authenticity of the data submitted by the other applicant, e.g., whether this data is truly independently generated by the applicant or from properly authorized sources. Either the right owner or the applicant can appeal to the CDA’s decision by administrative appeals or litigations.

To Prevent Abuse of Right

The Draft requires a data protection right owner to voluntarily disclose its protected data after the right is conferred. However, it is unclear whether the right owner is obligated to disclose any protected data that contains trade secrets or personal data.

In addition, an approved data protection right can be revoked by the CDA upon a third-party request if the relevant right owner fails to market and sell the protected drug within one year after receiving the NDA.

The updated regulatory data protection mechanism is encouraging, but several questions remain unclarified, for example, how an innovative drug is defined; which types of patents, if being successfully challenged, can render a generic drug eligible for data protection; the exclusivity term of first to market generics; and the definition of “independently generated data,” etc. We advise that pharmaceutical companies submit comments to the CDA by May 31, 2018.


1 See the General Office of the CPC Central Committee and the General Office of the State Council’s Opinions on Deepening the Reform of the Evaluation and Approval Systems and Encouraging Innovation on Drugs and Medical Devices dated October 2017.
2 See Article 34 of the Implementing Regulation of the Drug Administration Law (2016) and Article 20 of the Drug Registration Administration Measures (2007).
3 The U.S. grants a maximum 12 years of data protection period to biologics.
4 The EU grants a maximum 10 years of data protection period to innovative drugs.

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Ropes & Gray LLP | Attorney Advertising

Written by:

Ropes & Gray LLP
Contact
more
less

Ropes & Gray LLP on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up using*

Already signed up? Log in here

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
Privacy Policy (Updated: October 8, 2015):
hide

JD Supra provides users with access to its legal industry publishing services (the "Service") through its website (the "Website") as well as through other sources. Our policies with regard to data collection and use of personal information of users of the Service, regardless of the manner in which users access the Service, and visitors to the Website are set forth in this statement ("Policy"). By using the Service, you signify your acceptance of this Policy.

Information Collection and Use by JD Supra

JD Supra collects users' names, companies, titles, e-mail address and industry. JD Supra also tracks the pages that users visit, logs IP addresses and aggregates non-personally identifiable user data and browser type. This data is gathered using cookies and other technologies.

The information and data collected is used to authenticate users and to send notifications relating to the Service, including email alerts to which users have subscribed; to manage the Service and Website, to improve the Service and to customize the user's experience. This information is also provided to the authors of the content to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

JD Supra does not sell, rent or otherwise provide your details to third parties, other than to the authors of the content on JD Supra.

If you prefer not to enable cookies, you may change your browser settings to disable cookies; however, please note that rejecting cookies while visiting the Website may result in certain parts of the Website not operating correctly or as efficiently as if cookies were allowed.

Email Choice/Opt-out

Users who opt in to receive emails may choose to no longer receive e-mail updates and newsletters by selecting the "opt-out of future email" option in the email they receive from JD Supra or in their JD Supra account management screen.

Security

JD Supra takes reasonable precautions to insure that user information is kept private. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. However, please note that no method of transmitting or storing data is completely secure and we cannot guarantee the security of user information. Unauthorized entry or use, hardware or software failure, and other factors may compromise the security of user information at any time.

If you have reason to believe that your interaction with us is no longer secure, you must immediately notify us of the problem by contacting us at info@jdsupra.com. In the unlikely event that we believe that the security of your user information in our possession or control may have been compromised, we may seek to notify you of that development and, if so, will endeavor to do so as promptly as practicable under the circumstances.

Sharing and Disclosure of Information JD Supra Collects

Except as otherwise described in this privacy statement, JD Supra will not disclose personal information to any third party unless we believe that disclosure is necessary to: (1) comply with applicable laws; (2) respond to governmental inquiries or requests; (3) comply with valid legal process; (4) protect the rights, privacy, safety or property of JD Supra, users of the Service, Website visitors or the public; (5) permit us to pursue available remedies or limit the damages that we may sustain; and (6) enforce our Terms & Conditions of Use.

In the event there is a change in the corporate structure of JD Supra such as, but not limited to, merger, consolidation, sale, liquidation or transfer of substantial assets, JD Supra may, in its sole discretion, transfer, sell or assign information collected on and through the Service to one or more affiliated or unaffiliated third parties.

Links to Other Websites

This Website and the Service may contain links to other websites. The operator of such other websites may collect information about you, including through cookies or other technologies. If you are using the Service through the Website and link to another site, you will leave the Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We shall have no responsibility or liability for your visitation to, and the data collection and use practices of, such other sites. This Policy applies solely to the information collected in connection with your use of this Website and does not apply to any practices conducted offline or in connection with any other websites.

Changes in Our Privacy Policy

We reserve the right to change this Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our privacy policy will become effective upon posting of the revised policy on the Website. By continuing to use the Service or Website following such changes, you will be deemed to have agreed to such changes. If you do not agree with the terms of this Policy, as it may be amended from time to time, in whole or part, please do not continue using the Service or the Website.

Contacting JD Supra

If you have any questions about this privacy statement, the practices of this site, your dealings with this Web site, or if you would like to change any of the information you have provided to us, please contact us at: info@jdsupra.com.

- hide
*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.